General Information of Drug (ID: DM2E5Z7)

Drug Name
RG7882 Drug Info
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1 [1]
Pancreatic cancer 2C10 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM2E5Z7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Mesothelin (MSLN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CRS-207 DMXU5LZ Gastric adenocarcinoma 2B72 Phase 2 [4]
MORAb-009 DMCXNIP Mesothelioma 2C51.2 Phase 2 [5]
Anti-mesothelin CAR transduced PBL DMXI03L Cervical cancer 2C77.0 Phase 1/2 [6]
Anti-Mesothelin CAR-T cells DM4NMBW Gastric adenocarcinoma 2B72 Phase 1/2 [7]
CAR-T cells targeting Mesothelin DMMAQJ7 Cervical cancer 2C77.0 Phase 1/2 [8]
Anti-Mesothelin CAR-T cells DM4NMBW Gastric adenocarcinoma 2B72 Phase 1/2 [9]
HPN536 DM86OJ0 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
CAR-T cells targeting mesothelin DMPK35H Pancreatic cancer 2C10 Phase 1/2 [11]
TC-210 DM9S5I1 Cholangiocarcinoma 2C12.10 Phase 1/2 [12]
TC-510 DMSPG60 Breast cancer 2C60-2C65 Phase 1/2 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN Not Available [3]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028960)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Molecular Imaging As a Tool for Drug Development and Trial Design. JCO July 13, 2015 JCO.2015.61.6425
4 Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33.
5 Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36.
6 ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
7 ClinicalTrials.gov (NCT03545815) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
8 ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
9 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
10 Clinical pipeline report, company report or official report of Harpoon Therapeutics.
11 ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
12 Clinical pipeline report, company report or official report of TCR2 Therapeutics.
13 Clinical pipeline report, company report or official report of TCR2 Therapeutics